Quest for the right Drug
ארטריל ARTHRYL (GLUCOSAMINE SULFATE (CRYSTALLINE))
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
אבקה להכנת תמיסה : POWDER FOR SOLUTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Special Warning : אזהרת שימוש
4.4 Special warnings and precautions for use The presence of another joint disease, which would require alternative treatment, should be excluded. Exacerbation of asthma symptoms after initiation of glucosamine have been described. Therefore, asthmatic patients starting on glucosamine should be aware of potential worsening of symptoms. Caution is advised in treatment of patients with impaired glucose tolerance. Closer monitoring of blood sugar levels and where relevant insulin requirements may be necessary in diabetics at the beginning of treatment and periodically during treatment. No special studies were performed in patients with renal or hepatic insufficiency. The toxicological and pharmacokinetic profile of the product does not indicate limitations for these patients. However, administration to patients with severe hepatic or renal insufficiency should be under medical supervision. Patients with elevated blood cholesterol levels should consult their doctor or pharmacist before taking this medicinal product. Glucosamine should not be used in children and adolescents under the age of 18 years since safety and efficacy have not been established. If unusual signs or symptoms appear, or if any changes in the course of usual symptoms occur, the patient is recommended to consult the physician immediately. The powder for oral solution contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this pharmaceutical form. The powder for oral solution contains a source of phenylalanine. May be harmful for people with phenylketonuria. This medicinal product contains 151 mg sodium per sachet, equivalent to 7.5% of the WHO recommended maximum daily intake of 2 g sodium for an adult. To be taken into consideration by patients on a controlled sodium diet.
Effects on Driving
4.7 Effects on ability to drive and use machines No studies of the effects on the ability to drive and use machines have been performed. No important effects on the CNS or motor system are known that might impair the ability to drive or use machines. However, if headache, somnolence, tiredness, dizziness or visual disturbances are experienced, driving a car or operating machinery is not recommended (see section 4.8).
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף